Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Analysis of Long-term (Investment) Activity Ratios

Microsoft Excel

Long-term Activity Ratios (Summary)

Bristol-Myers Squibb Co., long-term (investment) activity ratios

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net fixed asset turnover 6.77 6.77 7.38 7.67 7.22
Net fixed asset turnover (including operating lease, right-of-use asset) 5.78 5.60 6.18 6.66 6.30
Total asset turnover 0.52 0.47 0.48 0.42 0.36
Equity turnover 2.96 1.53 1.49 1.29 1.12

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Bristol-Myers Squibb Co. net fixed asset turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Bristol-Myers Squibb Co. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Bristol-Myers Squibb Co. total asset turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Bristol-Myers Squibb Co. equity turnover ratio improved from 2022 to 2023 and from 2023 to 2024.

Net Fixed Asset Turnover

Bristol-Myers Squibb Co., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Revenues 48,300 45,006 46,159 46,385 42,518
Property, plant and equipment 7,136 6,646 6,255 6,049 5,886
Long-term Activity Ratio
Net fixed asset turnover1 6.77 6.77 7.38 7.67 7.22
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 10.97 10.89 11.76 11.00 8.73
Amgen Inc. 4.89 4.53 4.57 4.69 4.96
Danaher Corp. 4.78 5.25 7.96 7.77 6.83
Eli Lilly & Co. 2.63 2.64 2.81 3.15 2.83
Gilead Sciences Inc. 5.28 5.07 4.93 5.27 4.90
Johnson & Johnson 4.33 4.28 4.79 4.95 4.40
Merck & Co. Inc. 2.70 2.61 2.77 2.53 2.67
Pfizer Inc. 3.46 3.14 6.22 5.52 3.07
Regeneron Pharmaceuticals Inc. 3.09 3.16 3.23 4.62 2.64
Thermo Fisher Scientific Inc. 4.61 4.54 4.84 4.71 5.45
Vertex Pharmaceuticals Inc. 8.98 8.51 8.06 6.92 6.47
Net Fixed Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.18 4.12 4.98 4.98 4.31
Net Fixed Asset Turnover, Industry
Health Care 10.08 9.76 10.25 10.04 9.24

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Net fixed asset turnover = Revenues ÷ Property, plant and equipment
= 48,300 ÷ 7,136 = 6.77

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Bristol-Myers Squibb Co. net fixed asset turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Bristol-Myers Squibb Co., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Revenues 48,300 45,006 46,159 46,385 42,518
 
Property, plant and equipment 7,136 6,646 6,255 6,049 5,886
Operating lease right-of-use assets 1,224 1,390 1,220 919 859
Property, plant and equipment (including operating lease, right-of-use asset) 8,360 8,036 7,475 6,968 6,745
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 5.78 5.60 6.18 6.66 6.30
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
AbbVie Inc. 9.62 9.47 10.24 9.57 7.46
Amgen Inc. 4.51 4.08 4.13 4.23 4.58
Danaher Corp. 3.93 4.26 6.35 6.10 5.30
Eli Lilly & Co. 2.48 2.45 2.63 2.93 2.63
Gilead Sciences Inc. 4.83 4.57 4.51 4.77 4.34
Johnson & Johnson 4.11 4.07 4.54 4.72 4.18
Merck & Co. Inc. 2.55 2.45 2.60 2.33 2.43
Pfizer Inc. 3.08 2.72 5.25 4.64 2.79
Regeneron Pharmaceuticals Inc. 2.95 3.11 3.17 4.52 2.58
Thermo Fisher Scientific Inc. 3.97 3.89 4.13 3.98 4.82
Vertex Pharmaceuticals Inc. 4.26 6.79 6.13 5.32 4.83
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Pharmaceuticals, Biotechnology & Life Sciences 3.78 3.71 4.48 4.45 3.91
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care 8.36 7.96 8.24 7.94 7.24

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenues ÷ Property, plant and equipment (including operating lease, right-of-use asset)
= 48,300 ÷ 8,360 = 5.78

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Bristol-Myers Squibb Co. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024.

Total Asset Turnover

Bristol-Myers Squibb Co., total asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Revenues 48,300 45,006 46,159 46,385 42,518
Total assets 92,603 95,159 96,820 109,314 118,481
Long-term Activity Ratio
Total asset turnover1 0.52 0.47 0.48 0.42 0.36
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.42 0.40 0.42 0.38 0.30
Amgen Inc. 0.35 0.28 0.38 0.40 0.39
Danaher Corp. 0.31 0.28 0.37 0.35 0.29
Eli Lilly & Co. 0.57 0.53 0.58 0.58 0.53
Gilead Sciences Inc. 0.48 0.43 0.43 0.40 0.36
Johnson & Johnson 0.49 0.51 0.51 0.52 0.47
Merck & Co. Inc. 0.55 0.56 0.54 0.46 0.52
Pfizer Inc. 0.30 0.26 0.51 0.45 0.28
Regeneron Pharmaceuticals Inc. 0.38 0.40 0.42 0.63 0.50
Thermo Fisher Scientific Inc. 0.44 0.43 0.46 0.41 0.47
Vertex Pharmaceuticals Inc. 0.49 0.43 0.49 0.56 0.53
Total Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.43 0.40 0.47 0.45 0.39
Total Asset Turnover, Industry
Health Care 0.81 0.76 0.79 0.73 0.68

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Total asset turnover = Revenues ÷ Total assets
= 48,300 ÷ 92,603 = 0.52

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Bristol-Myers Squibb Co. total asset turnover ratio deteriorated from 2022 to 2023 but then improved from 2023 to 2024 exceeding 2022 level.

Equity Turnover

Bristol-Myers Squibb Co., equity turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Revenues 48,300 45,006 46,159 46,385 42,518
Total BMS shareholders’ equity 16,335 29,430 31,061 35,946 37,822
Long-term Activity Ratio
Equity turnover1 2.96 1.53 1.49 1.29 1.12
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 16.94 5.24 3.36 3.65 3.50
Amgen Inc. 5.45 4.32 6.77 3.63 2.58
Danaher Corp. 0.48 0.45 0.63 0.65 0.56
Eli Lilly & Co. 3.17 3.17 2.68 3.15 4.35
Gilead Sciences Inc. 1.48 1.18 1.27 1.28 1.34
Johnson & Johnson 1.24 1.24 1.24 1.27 1.31
Merck & Co. Inc. 1.39 1.60 1.29 1.28 1.90
Pfizer Inc. 0.72 0.67 1.06 1.06 0.67
Regeneron Pharmaceuticals Inc. 0.48 0.51 0.54 0.86 0.77
Thermo Fisher Scientific Inc. 0.86 0.92 1.02 0.96 0.93
Vertex Pharmaceuticals Inc. 0.67 0.56 0.64 0.75 0.71
Equity Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.27 1.15 1.24 1.27 1.22
Equity Turnover, Industry
Health Care 2.31 2.13 2.09 2.03 1.99

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Equity turnover = Revenues ÷ Total BMS shareholders’ equity
= 48,300 ÷ 16,335 = 2.96

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Bristol-Myers Squibb Co. equity turnover ratio improved from 2022 to 2023 and from 2023 to 2024.